Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masatoshi Shirane

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Anticancer Research|August 19, 2007
Chemosensitivity-related genes of breast cancer detected by DNA microarrayTadashi Ikeda, Hiromitsu Jinno, Masatoshi Shirane
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2010
[Microarray analysis of tumor xenograft model]Fumiko Fujita, Masatoshi Shirane, Kazushige Mori, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2006
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia modelsKaori Fujimoto-Ouchi, Etsuro Onuma, Masatoshi Shirane, et al.
Oncology Reports|January 3, 2012
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenograftsToshiki Iwai, Yoichiro Moriya, Masatoshi Shirane, et al.
Oncology Reports|September 30, 2010
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRASKoh Furugaki, Toshiki Iwai, Masatoshi Shirane, et al.
Anticancer Research|March 2, 2005
Plasminogen activator inhibitor-1 is a downstream mediator of the PGP9.5-related oncogenic pathway in esophageal squamous cell carcinomaKenji Hibi, Yasuhiro Kodera, Katsuki Ito, et al.
Cancer Chemotherapy and Pharmacology|November 12, 2009
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapyKaori Fujimoto-Ouchi, Fumiko Sekiguchi, Kaname Yamamoto, et al.
Oncology Letters|September 12, 2012
High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancersShinobu Umemura, Masatoshi Shirane, Susumu Takekoshi, et al.
Molecular Medicine Reports|April 8, 2011
Effect of erythropoietin on human tumor growth in xenograft modelsMotoyuki Kataoka, Yoichiro Moriya, Yoshiyuki Moriguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
Identification of S100A2 as a target of the DeltaNp63 oncogenic pathwayKenji Hibi, Shin-ichi Fujitake, Tsunenobu Takase, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Anticancer Research|August 19, 2007
Chemosensitivity-related genes of breast cancer detected by DNA microarrayTadashi Ikeda, Hiromitsu Jinno, Masatoshi Shirane
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 19, 2010
[Microarray analysis of tumor xenograft model]Fumiko Fujita, Masatoshi Shirane, Kazushige Mori, et al.
Cancer Chemotherapy and Pharmacology|September 30, 2006
Capecitabine improves cancer cachexia and normalizes IL-6 and PTHrP levels in mouse cancer cachexia modelsKaori Fujimoto-Ouchi, Etsuro Onuma, Masatoshi Shirane, et al.
Oncology Reports|January 3, 2012
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenograftsToshiki Iwai, Yoichiro Moriya, Masatoshi Shirane, et al.
Oncology Reports|September 30, 2010
Schedule-dependent antitumor activity of the combination with erlotinib and docetaxel in human non-small cell lung cancer cells with EGFR mutation, KRAS mutation or both wild-type EGFR and KRASKoh Furugaki, Toshiki Iwai, Masatoshi Shirane, et al.
Anticancer Research|March 2, 2005
Plasminogen activator inhibitor-1 is a downstream mediator of the PGP9.5-related oncogenic pathway in esophageal squamous cell carcinomaKenji Hibi, Yasuhiro Kodera, Katsuki Ito, et al.
Cancer Chemotherapy and Pharmacology|November 12, 2009
Preclinical study of prolonged administration of trastuzumab as combination therapy after disease progression during trastuzumab monotherapyKaori Fujimoto-Ouchi, Fumiko Sekiguchi, Kaname Yamamoto, et al.
Oncology Letters|September 12, 2012
High expression of thymidine phosphorylase in basal-like breast cancers: Stromal expression in EGFR- and/or CK5/6-positive breast cancersShinobu Umemura, Masatoshi Shirane, Susumu Takekoshi, et al.
Molecular Medicine Reports|April 8, 2011
Effect of erythropoietin on human tumor growth in xenograft modelsMotoyuki Kataoka, Yoichiro Moriya, Yoshiyuki Moriguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 2, 2003
Identification of S100A2 as a target of the DeltaNp63 oncogenic pathwayKenji Hibi, Shin-ichi Fujitake, Tsunenobu Takase, et al.
Pageof 2